tbuckley/cabot-search huggingface dataset:
Health Information Technology and the Electronic Medical Record
Authors: Robert E Henkin, Jay A Harolds
Journal: Clinical Nuclear Medicine (2010)

Health Information Technology and the Electronic Medical Record are becoming increasingly important in virtually all aspects of medicine. This includes computer-assisted decision support, the integration of all aspects of the health record, ability to access patient information no matter where a patient seeks care, cost control, and health care research and quality improvement. It also has ramifications for the education of health care professionals and general community members. This article briefly examines some of the most important aspects of this development.
ESFINTEROPLASTIA PANCREÁTICA COMO MANIOBRA TERAPÉUTICA ENDOSCÓPICA PARA TRATAMIENTO DE PATOLOGÍA PANCREÁTICA: PERFIL DE SEGURIDAD Y RESULTADOS
Authors: JJ Vila, D Ruiz-Clavijo, B González De La Higuera, E Valdivielso, A Iriarte, I Fernández-Urién, FJ Jiménez
Journal: Endoscopy (2014)

Introducción: La esfinteroplastia pancreática (EP) es poco habitual en CPRE con escasas referencias en la literatura, incluyendo la mayor serie publicada 4 casos.
Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine
Authors: Jeffrey Lefkovits, Edward F. Plow, Eric J. Topol
Journal: New England Journal of Medicine (1995)

Platelets have a key role in atherosclerosis, thrombosis, and acute coronary syndromes. Therapeutic manipulation of platelet function has focused principally on the use of aspirin, which has proved effective in many clinical situations, despite its relatively weak antiplatelet action. More recently, the platelet glycoprotein IIb/IIIa receptor has been identified as the pivotal mediator of platelet aggregation, making it a logical target for control of the platelet response to vascular injury. This review summarizes the current state of knowledge of the biology of glycoprotein IIb/IIIa receptors and examines the development of agents that inhibit these receptors — a diverse group of . . .
Abstract LB-286: Reconstitution of the human ovarian tumor-microenvironment in CD34-transplanted NOD-Scid-IL2Rγc null (NSG) mice
Authors: Marc Walter, Ananda Mookerjee, Selene Nunez-Cruz, Chongyun Fang, Andrea Facciabene, George Coukos, Nathalie Scholler, Gwenn Danet-Desnoyers
Journal: Cancer Research (2011)

Abstract The use of stem cell-derived human immune system NSG mice and orthotopic tumors to recapitulate the human ovarian tumor microenvironment represents a significant improvement over existing mouse models of cancer. However, the careful phenotyping of a human ovarian tumor microenvironment in NSG mice has not been reported. We characterized the human ovarian tumor microenvironment in NSG mice reconstituted with a full human immune system using cord blood-derived CD34+ cell transplantation, and injected with human ovarian tumor cells. Our findings demonstrated human B cell and T cell infiltration in both orthotopic and subcutaneous tumors. Orthotopic tumors showed a 3 to 4-fold increase of human CD3+ cell infiltration in comparison with subcutaneous tumors or spleens from tumor bearing mice, however, the overall CD4/CD8 T cell ratio was similar in both tumor sites. Tumor-infiltrating T cells included effector memory TEM cells and Treg cells. Orthotopic tumor dissociates also contained significantly more human macrophages (TAMs) than subcutaneous tumors or spleens from tumor bearing mice. While all macrophages were found to have an M1-like phenotype, TAM subsets could be distinguished from splenic macrophages by CD40 or HLA-DR expression and TNFβ secretion. Furthermore, TAMs phenotypic differences observed in orthotopic tumors were associated with faster tumor growth kinetics and metastasis. Finally, we found that, in addition to the murine origin of the tumor stroma, a significant number of mouse neutrophils and macrophages were also present. We propose that humanized mice bearing human tumors could be a valuable tool for the preclinical evaluation of targeted therapies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-286. doi:10.1158/1538-7445.AM2011-LB-286
Abstract 3092: Deregulation of miR-10b in osteosarcoma.
Authors: K. Amy Chen, Jordan P. Sand, Katherine A. Janeway, Stuart H. Orkin
Journal: Cancer Research (2013)

Abstract Osteosarcoma (OS) is the most common primary bone malignancy found in children and adolescents, but the underlying molecular pathogenesis is not yet well understood. Utilizing a genetically engineered mouse model of OS that faithfully recapitulates salient features of the human disease, we are able to examine potential molecular contributions, such as that of a class of small, regulatory RNAs called microRNAs (miRNAs), in the processes of tumor proliferation and tumor progression and/or metastasis. MiRNA expression profile of tumors isolated from primary and secondary (metastatic) tumor sites of the mouse model revealed significant differential expression of miRNAs between the two groups. MiR-10b was significantly down-regulated in metastatic tumors in comparison with their primary counterparts, and thus was hypothesized to play important roles in the process of metastatic progression and/or tumorigenesis. To determine its impact on invasiveness and/or proliferation of the tumor cells, miR-10b was re-expressed in metastatic cell lines and introduced through tail-vein or intramuscular injections into scid/nude mice. Quantitative analysis using a bioluminescence imaging system showed delayed metastatic progression, lessened pulmonary tumor burden, as well as decreased primary tumor size in animals injected with tumor cells over-expressing miR-10b as compared to the controls. These data suggest that miR-10b down-regulation contributes to the processes of metastasis and tumorigenesis in OS through altered interaction with its target genes. Currently, putative miR-10b gene targets generated by microarray and RNA-seq analysis are being validated to provide a better understanding of the molecular mechanisms underlying miR-10b regulation in OS, and to facilitate the discovery of pathways amenable to manipulation with novel therapeutics. Citation Format: K. Amy Chen, Jordan P. Sand, Katherine A. Janeway, Stuart H. Orkin. Deregulation of miR-10b in osteosarcoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3092. doi:10.1158/1538-7445.AM2013-3092
SOLUBLE ST2 AND HIGH SENSITIVITY CARDIAC TROPONIN-T LEVELS PREDICT ATRIAL FIBRILLATION ABLATION OUTCOME
Authors: Vincent Y. See, Timm Dickfeld, Stephen Shorofsky, Anastasios Saliaris, Benjamin Remo, Thomas Klein, Andrew Zohlman, Robert Christenson, Christopher DeFilippi
Journal: Journal of the American College of Cardiology (2016)
PHARMACODYNAMIC EFFECTS OF SWITCHING FROM PRASUGREL TO TICAGRELOR: RESULTS OF THE PROSPECTIVE, RANDOMIZED SWAP (SWITCHING ANTI PLATELET)-3 STUDY
Authors: Gabriel Todd Faz, Fabiana Rollini, Francesco Franchi, Yongwhi Park, Jung Rae Cho, Estela Thano, Jenny Hu, Megha Kureti, Niti Aggarwal, Ashwin Durairaj, Latonya Been, Martin Zenni, Luis Guzman, Siva Suryadevara, Patrick Antoun, Theodore Bass, Dominick Angiolillo
Journal: Journal of the American College of Cardiology (2016)
Preterapeutic stagging of the esophageal cancer using endoscopic ultrasound
Authors: R Mesihovic, N Vanis, M Gribajcevic
Journal: Endoscopy (2006)

Patients with verifyed early stage of the esophageal carcinoma are presented with a very good prognosis, however all over the world patients present themselves with advanced stages thus minoring the chances for surivival. Data obtained form the USA programme are presenting informations about 5 year survival period in 14% of the cases. On the other hand, prospective multicentric European study refers to the same period in 10%. UK studies are presenting age-standardised relative rate of survival at 25% for the first 2 years and corresponding 4.8%-6.3% for the 5 year period/1/. Prognoses are deteriorating with the progression of the primary tumour, thus patients in stage IVare facing 5 year survival period in less than 5% of the cases. 5 year survival period for patients who undervent surgery in N0 stage, is 40%-60% comparing to 5%-17% for those in confirmed N1 stage. Patients who undergo surgery in confirmed T3N1 stage are faced with 5 year surivial period in 8%-10% of the cases, emphasizing the fact that these tumours are operable, but rarely curable by surgery itself. Neoadjuvant therapy use is increasing for the patients in stages IIB and IIC (local aprogression of the tumour), aiming to decrease the size of the primary cancer prior to surgery thus increasing the rate of long term survival. Our experiences brought out in this study coorelate with the foreign results thus againg stressing the fact that the exact stagging of the tumour is the basics for the treatement as well as the right choice of the patients for surgery treatement, and those who need neoadjuvant therapy.
AB0281 The Potential Cellular Marker for Disease Activity of Rheumatoid Arthritis: Circulating CD4+Cd161+ T Cells
Authors: P. Zhu, K. Zhang, J. Miao
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Rheumatoid arthritis (RA) is a common autoimmune disease that is primarily driven by effector Tcells, in particular by Th17 cells which are contained within CD4+CD161+ Tcells. <h3>Objectives</h3> We aim to evaluate the levels and cytokine secretion of circulating CD4+CD161+ T cells and Th17-related cytokines in patients with RA, and to elucidatetheir correlations with RA disease activity. <h3>Methods</h3> Flow cytometry was used to analyze the surface phenotype and cytokine production of peripheral blood from 42 patients with RA and 11 healthy controls (HC). Plasma levels of Th17-related cytokines were measured by cytometric bead array (CBA). Additionally, disease activity was evaluated by the 28-joint Disease Activity Score (DAS28). Spearman9s rank correlation and Receiver operating characteristic (ROC) curve were used for analyzing the relation of the indicators and disease activity. <h3>Results</h3> Mainly circulating interleukin (IL)-17–producing cells were contained within the CD4+CD161+ T cells in patients with RA and HC. The levels of circulating CD4+CD161+ T cells, CD4+CD161+IL-17+IFN-γ+ cells (CD161+ Th17 cells), IL-17 and IL-6 in RA patient were significantly elevated and correlated strongly with disease activity indices. Accordingly, enhanced percentages of these indicators were observed in RA patients with active disease status (DAS28 &gt;3.2) than in those with low disease status (DAS28 ≤3.2). In contrast, the percentages of circulating CD4+CD161+IL-17−IFN-γ+ cells (CD161+ Th1 cells) were significantly decreased and negatively correlated with disease activity indices in RA patients. ROC curve analysis identifiedthe composite indicator which was combined by the levels of CD4+CD161+ T cells and erythrocyte sedimentation rate (ESR) distinguished disease activity with 91.7% sensitivity and 94.4% specificity. <h3>Conclusions</h3> Circulating CD4+CD161+ T cells may consider as a potentially cytologic biomarker of RA disease activity. Moreover, the composite indicator including CD4+CD161+ T cells and ESR may be a useful indicator for monitoring disease activity and treatment response in RA. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3453
BENEFITS OF TRANSCATHETER AORTIC VALVE REPLACEMENT IN PATIENTS WITH UNCLAMPABLE CALCIFIED AORTA: QUANTIFYING REDUCED MORTALITY RISK IN THE TAVR ERA
Authors: Maroun B. Yammine, Julius Ejiofor, Siobhan McGurk, Anthony Norman, Prem Shekar, Lawrence Cohn, Sary Aranki, Pinak Shah, Tsuyoshi Kaneko
Journal: Journal of the American College of Cardiology (2016)
EIGHT-YEAR TARGET LESION REVASCULARIZATION RATES IN BARE METAL VERSUS FIRST AND SECOND GENERATION DRUG ELUTING STENTS: ANALYSIS OF 22,957 STENTED LESIONS
Authors: Sanaa Badour, Yumiko Kanei, Kamellia Dimitrova, Joseph Habib, John Fox, Robert Tranbaugh, Thomas Schwann, Samir Alam, Robert Habib
Journal: Journal of the American College of Cardiology (2015)
PATRONES DE USO DE INTERNET EN LOS PACIENTES SOMETIDOS A ENDOSCOPIA DIGESTIVA: ¿ES ÚTIL UNA PÁGINA ESPECÍFICA DE INFORMACIÓN SOBRE EL PROCEDIMIENTO?
Authors: A Braithwaite, G Poppele, M Bustamante, L Argüello, M Ponce, V Pons
Journal: Endoscopy (2012)

Objetivo:1) conocer las características del uso de internet de los pacientes sometidos a endoscopia; 2) valorar su uso para obtener información sobre la prueba; 3) evaluar el interés de los pacientes en disponer una página específica de información y qué factores se relacionan con dicho interés. Pacientes y método: entre abril y julio de 2012 se entregó una encuesta a todos los pacientes ambulatorios que acudieron a realizarse una endoscopia. Se recogieron variables demográficas (edad, sexo, etc.), de información recibida (satisfacción, etc.), del uso de internet (sitio de acceso, frecuencia, etc.), y del uso de internet para buscar información sobre la prueba (sitios de búsqueda, etc.). Finalmente se preguntó sobre su interés en disponer de una página de internet con información sobre la prueba Resultados: 932 pacientes respondieron a 948 encuestas. 458 (48,9%) fueron mujeres. Mediana de edad 60,3 años (rango 18–92). 525 (56%) tenían conexión de internet en casa. 178 (19,0%) se conectaban más de 6 horas a la semana. 208 (22,2%) utilizaban redes sociales. 230 (24,5%) utilizaban internet para resolver dudas de salud. 106 pacientes (11,2%) buscaron información sobre la prueba principalmente en Google (76,8%). 334 pacientes (35,2%) deseaban disponer de una página de información específica. En el análisis univariante, edad Conclusión: El diseño de una página específica de información sobre las pruebas endoscópicas parece relevante, especialmente para pacientes poco satisfechos con la información obtenida de su médico y que manejan habitualmente internet.
Incidental Visualization of Pancreatic Cancer on Tc-99m MDP Bone Scan
Authors: S S Sun, M K Tsai, C A Chen, C H Kao
Journal: Clinical Nuclear Medicine (2001)

SUN, SHUNG-SHUNG M.D.*; TSAI, MIN-KUEI B.Sc.†; CHEN, CHAO-AN M.D.‡; KAO, CHIA-HUNG M.D.* Author Information
Clinical performance of PCA3 and TMPRSS2:ERG urinary biomarkers for African American men undergoing prostate biopsy.
Authors: Allison H. Feibus, Oliver Sartor, Raju Thomas, Michael M. Maddox, Benjamin Lee, Justin Levy, Carrie A. Stewart, Julie Wang, Krishnarao Moparty, Jonathan L. Silberstein
Journal: Journal of Clinical Oncology (2015)

91 Background: Urinary assaysfor PCA3 and TMPRSS2:ERG (T2:ERG) fusion are established biomarkers for the detection of prostate cancer (PCa). However few African Americans (AA) have been included in previous studies. We sought to determine the performance characteristics of these assays in a racially diverse group of men who elected to undergo prostate biopsy. Methods: Following IRB approval, from 12/2013-10/2014, post digital rectal exam urine was collected in 152 patients without a diagnosis of PCa, prior to biopsy. PCA3 and T2:ERG RNA copies were quantified using transcription-mediated amplification assays and normalized to PSA mRNA copies. Results: Of the 152 patients who met study inclusion, 93 (61%) were AA, 59 were non-AA (39%); 72(47%) were diagnosed with PCa (55% AA, 36% non-AA). Both PCA3 and T2:ERG scores were greater in men with biopsy-proven PCa, those with ≥3 PCa cores, ≥33.3% PCa cores, &gt;50% PCa involvement of greatest biopsy core and Epstein significant PCa (all p-values ≤ 0.02). PCA3 but not T2:ERG scores were greater in men with Gleason grade ≥7 (p = 0.0003). ROC analyses for prediction of biopsy outcome resulted in AUCs of 0.7, 0.61 and 0.59 for PCA3, T2:ERG and serum PSA. For the subgroup of AA, PCA3 and T2:ERG scores were greater in men with biopsy-proven PCa, those with ≥3 PCa cores, ≥33.3% PCa cores, &gt;50% PCa involvement of greatest biopsy core and Epstein significant PCa (all p-values ≤0.01). Both PCA3 and T2:ERG scores were greater in men with Gleason grade ≥7 (p ≤ 0.03). ROC analyses for prediction of biopsy outcome for AA only resulted in AUCs of 0.66, 0.66 and 0.58 for PCA3, T2:ERG and serum PSA. For the non-AA cohort, PCA3 scores were greater in men with biopsy-proven PCa, those with ≥3 PCa cores, ≥33.3% PCa cores, &gt;50% PCa involvement of greatest biopsy core, Epstein significant PCa and Gleason grade ≥7 (all p-values ≤ 0.03). T2:ERG did not reach significance for any of these variables. In this subgroup, ROC analyses for prediction of biopsy outcome resulted in AUCs of 0.73, 0.54 and 0.56 for PCA3, T2:ERG and serum PSA. Conclusions: In AA men undergoing prostate biopsy, both PCA3 and T2:ERG urinary assays demonstrate clinical utility in predicting biopsy outcome and PCa disease characteristics.
Abstract 4233A: The opposite effects of doxorubicin on bone marrow cells versus cancer cells <i>in vivo</i> depend on glucosylceramide synthase
Authors: Kaustubh N. Bhinge, Vineet Gupta, Sharon Meyer, Benny Blaylock, Qian-Jin Zhang, Yong Yu Liu
Journal: Cancer Research (2012)

Abstract Bone marrow suppression and tumor drug resistance are adverse effects observed in patients with chemotherapy severely limit cancer treatments. It is unclear by which cellular mechanism anticancer drugs suppress bone marrow while drug-resistant tumor survives. We report that due to the difference in the glucosylceramide synthase (GCS) that catalyzes ceramide glycosylation determining ceramide-induced apoptosis or glycosphingolipid mediated maintenance of stem cells, doxorubicin can eliminate bone marrow stem cells and expand cancer stem cells. Doxorubicin treatments significantly decreased the number of bone marrow stem cells (BMSCs, ABCG2+) and sphere formation in dose-dependent fashion (1-5 mg/kg). In tumor-bearing mice, doxorubicin treatments (6 days) significantly decreased bone marrow stem cells and peripheral blood cells at 2 mg/kg and 5 mg/kg. In contrast, doxorubicin increased the number of breast cancer stem cells (BCSCs, CD24-/CD44+/ESA+) more than 3 times at 5 mg/kg treatment. Furthermore, silencing GCS with MBO-asGCS prevented BCSC number increase. Similarly, therapeutic-dose of doxorubicin (1 mg/kg/week, i.p., for 42-days), decreased bone marrow stem cells and increased breast cancer stem cells. Breast cancer cells, but not bone marrow cells, highly expressed glucosylceramide synthase (GCS) which was associated with pluripotency of stem cells. These results indicate that doxorubicin may have the opposite effects, suppressing BMSC versus expanding BCSC in vivo, and GCS is a determinant for the differentiated responsiveness between bone marrow cells, and breast cancer cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4233A. doi:1538-7445.AM2012-4233A
Healthy people need fewer preoperative tests for elective surgery, says NICE
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Patients undergoing elective surgery do not need to undergo a raft of preoperative tests unless they have underlying health conditions or are having a complex or major procedure, the National Institute for Health and Care Excellence (NICE) has said.

In an updated clinical guideline on routine preoperative tests,1 NICE recommends reducing the number of routine tests given to healthy patients undergoing surgery, as well as ensuring that test results known to a patient’s general practice are made available with referrals, to avoid unnecessary testing.

The updated guideline follows guidance published in January by the Association of Anaesthetists of Great Britain and Ireland jointly with the British Hypertension Society, which recommended that GPs include information on a patient’s blood pressure in referral letters for elective surgery and refer only those whose blood pressure was lower than 160/100 mm Hg for the …
Sydenham's Chorea, or St. Vitus's Dance
Authors: Fei Wei, Jie Wang
Journal: New England Journal of Medicine (2013)

A previously healthy 11-year-old boy presented with rapid, irregular, aimless, involuntary movements of the limbs, neck, and trunk. These uncontrollable movements began 1 month earlier, initially affecting only his left limbs but later extending to other parts of his body.
Double-Phase Tc-99m MIBI Scintigraphy in Secondary Hyperparathyroidism Relapsing After Parathyroidectomy and Removal of a Parathyroid Autograft
Authors: MARCEL H. THELEN, TORSTEN KUWERT, HARTMUT LERCH, CHRISTIAN WITTING, BERNHARD WINTERBERG, OTMAR SCHOBER
Journal: Clinical Nuclear Medicine (1996)

A 53-year-old woman with chronic renal failure had secondary hyperparathyroidism relapsing after undergoing a second parathyroidectomy and excision of an autologous parathyroid graft that had been implanted after her first parathyroidectomy. Double-phase scintigraphy with Tc-99m MIBI disclosed pathologic MIBI uptake in the right anterior thorax where the parathyroid transplant had been placed. Histopathologic examination of three nodules excised from this region yielded hyperplastic parathyroid tissue. This case report further illustrates the value of double-phase Tc-99m MIBI scintigraphy in atypical cases of hyperparathyroidism.
SEX DIFFERENCES IN GERIATRIC IMPAIRMENTS AND IN-HOSPITAL MANAGEMENT STRATEGIES AMONG OLDER ADULTS HOSPITALIZED FOR AMI: THE SILVER AMI STUDY
Authors: Michael Nanna, Mary Geda, Terrence Murphy, Sui Tsang, Rachel Dreyer, Dharshan Lakshminarayan, Francine Welty, Sarwat Chaudhry, John Dodson
Journal: Journal of the American College of Cardiology (2016)